PHI BIOMED LEADING THE FUTURE OF SMART NANOMEDICINES

HOME > R&BD > Core Technology

Core Technology

Flt1 Peptide - Hyaluronic Acid Conjugate Nanoparticles
Contact Information
1 Company PHI BioMed, Korea
2 Manager Hye Ryoung Lee, MBA (aosora2001@yahoo.com)
3 Web Page http://www.phibiomed.co.kr
Researcher
4 Institute (Researcher) POSTECH (Prof. Sei Kwang Hahn)
5 Web Page http://bnl.postech.ac.kr
Technology
6 Title Flt1 Peptide - Hyaluronic Acid Conjugate Nanoparticles
7 Composition Hyaluronic Acid, Flt1 Peptide, Chemical Drug
8 Application
  • Anti-angiogenic therapy
  • Ocular neovascularization, diabetic retinopathy, asthma, cancer
9 Competitive Advantage
  • Combination therapy of Flt1 peptide and drugs
  • Tailored ocular therapy with hyaluronic acid derivaties
  • Tailored pulmonary therapy with hyaluronic acid derivatives
10 Stage of Development Preclinical
11 Data Files
  • In Vitro biological activity
  • In Vivo release test
  • Inhibition of corneal neovascularization in rats
  • Inhibition of vascular hyperpermeability in rats
  • PK in rats
12 Test Model Drug Flt1 peptide, Genistein, Dexamethasone, Doxorubicin, Epirubicin
13 Representative Figure [Biomaterials 30, 6026 (2009) & 32, 3115 (2011)]
Intellectual Property
14 Domestic Patents filed/granted Patent No. 10-1296329
15 International(PCT) Patents filed/granted US 11/326,477
16 Ownership PHI BIOMED
17 Proposal Type Clinical Co-development/Licensing Out
TOP